Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Meta Expands AI Training With Employee Activity Tracking Tools 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
CAMBRIDGE, Mass., March 01, 2016 -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases based on an adeno-associated virus (AAV) gene delivery technology, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will present at two upcoming investor conferences:
- Cowen and Company 36th Annual Healthcare Conference
Monday, March 7, 2016 at 3:20 p.m. Eastern Time
The Boston Marriott Copley Place, Boston, MA
- 28th Annual ROTH Conference
Monday, March 14, 2016 at 12:00 p.m. Pacific Time
The Ritz Carlton Hotel, Dana Point, CA
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.dimensiontx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.
About Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is a leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency and GSDIa, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit www.dimensiontx.com.
Contacts Burns McClellan, on behalf of Dimension Therapeutics, Inc. Justin Jackson, 212-213-0006, ext. 327 [email protected]
